Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.
1. A pharmaceutical composition for treating a host having a viral infection for a virus from the Flaviviridae family of viruses, comprising an inhibiting agent, wherein the inhibiting agent has the following structure:
2. The pharmaceutical composition of claim 1 , further comprising a second agent for treating the viral infection.
3. The pharmaceutical composition of claim 2 , wherein the second agent is selected from the group consisting of: an anti-HCV therapeutic agent, an HCV NS3 protease inhibitor, an HCV NS5B RNA-dependent RNA polymerase inhibitor, a thiazolide, sustained release thiazolide, a nucleoside analog, and an interferon-alpha.
4. A pharmaceutical composition for treating a host having a viral infection for a virus from the Flaviviridae family of viruses, comprising an inhibiting agent, wherein the inhibiting agent has the following structure:
wherein R 1 is
wherein R 2 is
n is 1, and where X is
wherein each of R 4 -R 7 is independently selected from the group consisting of:
5. The pharmaceutical composition of claim 4 , further comprising a second agent for treating the viral infection.
6. The pharmaceutical composition of claim 5 , wherein the second agent is selected from the group consisting of: an anti-HCV therapeutic agent, an HCV NS3 protease inhibitor, an HCV NS5B RNA-dependent RNA polymerase inhibitor, a thiazolide, a sustained release thiazolide, a nucleoside analog, and an interferon-alpha.